+

WO2001097839A1 - Vaccins recombines contre le virus de la bursite infectieuse - Google Patents

Vaccins recombines contre le virus de la bursite infectieuse Download PDF

Info

Publication number
WO2001097839A1
WO2001097839A1 PCT/IL2000/000360 IL0000360W WO0197839A1 WO 2001097839 A1 WO2001097839 A1 WO 2001097839A1 IL 0000360 W IL0000360 W IL 0000360W WO 0197839 A1 WO0197839 A1 WO 0197839A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibdv
plant
vaccine
virion protein
disease virus
Prior art date
Application number
PCT/IL2000/000360
Other languages
English (en)
Inventor
Yehuda Stram
Arie Rogel
Orit Edelbaum
Ilan Sela
Yehuda Zanberg
Yehoshua Shachar
Eli Khayat
Tanya Gontmakher
Original Assignee
Rahan Meristem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rahan Meristem filed Critical Rahan Meristem
Priority to AU2000252449A priority Critical patent/AU2000252449A1/en
Priority to EP00937165A priority patent/EP1296710A4/fr
Priority to PCT/IL2000/000360 priority patent/WO2001097839A1/fr
Publication of WO2001097839A1 publication Critical patent/WO2001097839A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/517—Plant cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • This invention provides a transgenic plant and/or bacteria containing empty particles of Infectious Bursal Disease Virus (IBDV).
  • IBDV Infectious Bursal Disease Virus
  • This invention further provides a vaccine for protecting an avian against IBDV which comprises a transgenic plant or a bacteria containing empty particles of IBDV.
  • This invention further provides a method for protecting an avian against IBDV comprising a transgenic plant or bacteria containing empty particles of IBDV.
  • the common mucosal immune system by way of the secretory immunoglobulin response, provides a first line of resistance to infection across mucosal surfaces in vertebrates [J. Mestecky, "The common mucosal immune system and current strategies for induction of immune responses in external secretions," J. Clin. Immunol., 7, (1987) pp. 265-75].
  • the mucosal immune system consists of molecules, cells, and organized lymphoid structures intended to provide immunity to pathogens that invade mucosal surfaces. Mucosal infection by intracellular pathogens results in the induction of cell-mediated immunity, as manifested by CD4-positive (CD4+) T helper-type 1 cells, as well as CD8+ cytotoxic T-lymphocytes. These responses are normally accompanied by the synthesis of secretory immunoglobulin A (S-lgA) antibodies, which provide an important first line of defense against invasion of deeper tissues by these pathogens.
  • CD4-positive (CD4+) T helper-type 1 cells as manifested by CD8+ cytotoxic T-lymphocytes.
  • S-lgA secretory immunoglobulin A
  • Vaccines are administered to humans and animals to induce their immune systems to produce antibodies against viruses, bacteria, and other types of pathogenic organisms. In the economically advanced countries of the world, vaccines have brought many diseases under control. Vaccines that stimulate the mucosal immune system can be used to immunize hosts, generally via an oral route, against pathogens that are transmitted via a mucosal surface. [See for example Shalaby, "Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies", Clin. Immunol. Immunopathol., 74(2), 1995, pp.
  • IBD Infectious Bursal Disease
  • Gumboro Disease is a highly contagious viral disease of young chickens which is characterized by the destruction of lymphoid follicles in the bursa of Fabricius. Symptoms include depression, diarrhea, muscular hemorrhage, necrosis of the bursa and severe damage to the immune system. Mortality of infected birds is high, and survivors exhibit slow growth and high susceptibility to other infectious diseases. The disease attacks young chickens, usually up to 6 weeks of age. Susceptible chickens less than three weeks old do not exhibit outward clinical signs of the disease but have a marked infection characterized by gross lesions of the bursa.
  • IBDV Infectious Bursal Disease Virus
  • IBDV is the causative agent of IBD.
  • IBDV is a pathogen of major economic importance to the world's poultry industries.
  • the virus belongs to the genus Avibirnavirus of the family Bimaviridae. Members of this family contain a genome composed of two double-stranded (ds) RNA segments designated A and B.
  • the smaller genome segment B (approximately 2.8 kbp) encodes VP1 , the putative virion-associated RNA polymerase, whereas the larger genome segment A (approximately 3.3 kbp) encodes VP2, VP3, and VP4 as a precursor polyprotein.
  • the genome segment A sequence also has a small open reading frame (ORF) overlapping the 5' end of the polyprotein ORF in a different reading frame and is capable of encoding a 17 kDa polypeptide.
  • ORF open reading frame
  • the function of this protein remains unknown although the polypeptide is made in IBDV-infected cells and has been designated VP5.
  • VP4 has been found to be a protease that is responsible for processing of the precursor polyprotein into VPX (the precursor of VP2), VP3 and VP4.
  • the major capsid protein, VP2 is the main host-protective antigen of IBDV.
  • VP2 and VP3 are the structural proteins of IBDV and are necessary for virion assembly.
  • the present invention provides a transgenic plant comprising empty particles of Infectious Bursal Disease Virus (IBDV).
  • IBDV Infectious Bursal Disease Virus
  • the empty particles of the IBDV comprise one or more of virion protein 2 (VP2), virion protein 3 (VP3), and/or virion protein 4 (VP4).
  • the plant is a tobacco plant. In one embodiment, the plant is a potato plant.
  • the present invention further provides a vaccine for protecting an avian against IBDV that comprises a plant having an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the plant is a tobacco plant. In one embodiment, the plant is a potato plant.
  • the present invention further provides a bacteria comprising empty particles of the IBDV.
  • the empty particles of the IBDV comprise one or more of virion protein 2 (VP2), virion protein 3 (VP3), and/or virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • the present invention further provides a vaccine for protecting an avian against IBDV that comprises a bacteria having an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • the present invention further provides a method of immunizing an avian comprising administering to the avian a transgenic plant containing an effective amount of a vaccine comprising an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the plant is a tobacco plant.
  • the plant is a potato plant, in one embodiment, the avian is selected from the group consisting of chicken, turkey, goose, duck, pheasant, quail, pigeon and ostrich.
  • the present invention further provides a method of immunizing an avian comprising administering to the avian bacteria containing an effective amount of a vaccine containing an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • the avian is selected from the group consisting of chicken, turkey, goose, duck, pheasant, quail, pigeon and ostrich.
  • FIGURE 1 is a schematic representation of the PCR strategy for amplifying the entire IBDV fragment A genome. The size of the fragment is scaled in the bottom line;
  • FIGURES 2 A-C are photographs depicting agarose gel electrophoresis of amplified cDNA fragments of IBDV fragment A genome, stained with ethidium bromide and viewed over a UV lamp.
  • FIGURES 3 A-C are identical to FIGURES 3 A-C:
  • Figure 3B is a
  • FIG. 3C is a schematic representation of the pKVI206
  • FIGURE 4 depicts the nucleotide sequence of the amplified IBDV cDNA fragment in pKVI206;
  • FIGURES 5 A-C are photographs showing the expression and processing of IBDV proteins in BL21 E. Coli cells.
  • Figure 5A depicts a coomassie blue stained SDS polyacrylamide gel.
  • Figure 5B depicts a western blot using anti-IBDV serum.
  • Figure 5C depicts a western blot using anti-IBDV antibodies of purified IBDV proteins.
  • FIGURE 6 is a photograph showing the scanning electron microscope (SEM) microscopy of IPTG induced E. Coll cells (pKVI206-BL21 )
  • FIGURE 7 is photograph showing the Western blot analysis of anti-IBDV
  • FIGURE 8 is a schematic representation of the structure of the binary plasmid pBi203-IBDV
  • FIGURES 9 A and B are photographs showing the RT-PCR of an IBDV internal sequence in transgenic potato plants indicating the expression of IBDV RNA in the tubers. The arrow indicates the amplified PCR product.
  • FIGURE 10 is a photograph of an autoradiograph demonstrating IBDV protein expression in plants.
  • Figure 11 is a photograph showing the scanning electron microscope (SEM) microscopy of leaf or tuber tissue from transgenic potato or tobacco plants harboring IBDV particles (indicated by arrows).
  • the present invention provides a transgenic plant comprising empty particles of Infectious Bursal Disease Virus (IBDV).
  • IBDV Infectious Bursal Disease Virus
  • the empty particles of the IBDV comprise one or more of virion protein 2 (VP2), virion protein 3 (VP3), and/or virion protein 4 (VP4).
  • the plant is a tobacco plant. In one embodiment, the plant is a potato plant.
  • empty particle means a virus particle of the IBDV that is devoid of genetic elements and that permits replications.
  • transgenic plants In order to produce plant cells that express the assembled viral proteins, transgenic plants must be created containing therein the assembled viral proteins.
  • a transgenic plant is a plant expressing in at least some of the cells of the plant a recombinant viral immunogen.
  • the preferred method of administration of the vaccine is comprised of feeding the animals with the transgenic plants.
  • the transgenic plant of the invention in preferred embodiments, is an edible plant.
  • an edible plant or portion thereof of is one which is not toxic when injested by a mammal to be treated with the vaccine produced in the plant.
  • the edible part of the plant is used as a dietary component, while the vaccine is administered in the process.
  • the edible portions of the plant include the fruits, leaves, stems, roots or seeds of said plant.
  • particles were extracted from plant cells such as those of tobacco leaves or potato tubers and administered by injection. Any plant can be utilized which is able to be ingested by the animal which is fed the transgenic plant cells.
  • tobacco or potato plants are used, because in these plants the expression is constitutive. By constitutive, it is meant that all of the organs of the plants express the antigens.
  • Some examples of applicable methods include, but are not limited to, growing whole plants from single cells.
  • single cells usually from a callus-
  • the cellulose wall of the plant cells can be removed at this time, thus making the protoplast capable of taking up DNA.
  • the cells are then given sufficient nutrients and plant hormones, auxins and cytokinins, for successful regeneration of an entire plant as is commonly known by one skilled in the art.
  • the resulting plant therefore contains therein the desired DNA.
  • leaf disk technique Another example of an applicable method, is the leaf disk technique. This simple technique involves making small leaf disks by punching holes in a leaf. These holes are then inoculated with a recombinant plasmid that contains both a selectable marker and a desired transgene carried by a bacterium, for
  • the present invention further provides a bacteria comprising empty particles of the IBDV.
  • the empty particles of the IBDV comprise one or more of virion protein 2 (VP2), virion protein 3 (VP3), and/or virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • the present invention further provides a vaccine for protecting an avian against IBDV which comprises a plant having an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4) in a suitable carrier.
  • the plant is a tobacco plant.
  • the plant is a potato plant.
  • the present invention further provides a vaccine for protecting an avian against IBDV that comprises bacteria having an effective immunizing amount of empty particles in the IBDV.
  • the empty particles of IBDV comprises virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • a vaccine is a composition which, when contacted with a mammal, is capable of eliciting an immune response.
  • the empty particles of IBDV comprise Fragment A of
  • IBDV which encodes for virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4), in a suitable carrier.
  • the entire expressed assembled fragment A containing the viral proteins VP2, VP3 and VP4 is expressed in either the plant or bacterial expression vector, rather than the subunit vaccine comprising individual proteins VP2, VP3 or VP4. It has been established previously that in many cases immunization with only one recombinant viral protein, even with the most immunogenic one, does not necessarily induce the necessary protection state. However, it has been shown that immunization can be guaranteed with a fully assembled virion, achieved by expression of fragment A of IBDV.
  • the suitable carrier is a vector.
  • vector refers to an autonomously replicating DNA molecule.
  • Other terms that are analogous to “vector” are “cloning vectors” and “vehicles”.
  • Vectors that comprise the DNA encoding for a clone of the expression system are also provided by the present invention.
  • the vectors can be constructed by those skilled in the art and should contain all expression elements necessary to achieve the desired transcription of the sequences.
  • Expression systems for vectors include bacteria, yeast, mammalian and insect cells. Plasmids and bacteriophage are examples of vectors.
  • Plasmids are circular DNA duplexes that contain the requisite genetic machinery, such as a replication origin, and that confer beneficial characteristics to their hosts, such as resistance to antibiotics and mechanisms for recovery of the nucleic acids.
  • plasmids contain a number of conveniently located restriction endonuclease sites into which the DNA to be cloned may be inserted. Some plasmids replicate under stringent control - once per cell division. Other plasmids are under relaxed control - they are normally present in 10 to as many as 700 copies per cell. Plasmids may be used to clone DNAs of up to 10 kb.
  • Bacteriphages are cloning vectors that are used to clone DNAs of up to 16 kb.
  • Chimeric phage DNA containing the desired DNA can be introduced into the host cells by infecting them with phages formed from the DNA by an in vitro packaging system. Phages can also be used to clone longer DNA inserts. Examples of other vectors include baculoviruses and retroviruses, DNA viruses, liposomes and other recombination vectors. One of ordinary skill in the art will know which host systems are compatible with a particular vector.
  • the vaccine comprises bacteria containing empty particles of IBDV Fragment A inserted in a vector suitable for expression in bacteria.
  • the bacteria is E. Coli.
  • the £. Coli expression vector is pET21a.
  • the nucleic acid IBDV fragment A is synthesized and cloned into a vector suitable for expression in bacteria, preferably E. Coli. Synthesis of the nucleic acid involves the design of specific primers (as set forth in the examples below), which are then used in a Large and Accurate RT-PCR (LA-RT-PCR) process for developing the IBDV fragments to be cloned into the vector.
  • LA-RT-PCR Large and Accurate RT-PCR
  • an additional fragment is cloned into the genome between the promoter and the terminator of the expression vector.
  • the resulting plasmid is then capable of transforming bacterial cells as required for vaccination.
  • the cDNA sequence encoding IBDV Fragment A inserted in the E. Coli expression vector pET21a is set for the in SEQ ID No. 1 , as set forth in Figure 4.
  • the vaccine comprises a plant containing empty particles of IBDV Fragment A inserted in a vector suitable for expression in plants.
  • the nucleic acid IBDV fragment A is synthesized and cloned into a vector suitable for expression in plants, such as potato or tobacco, as set forth in the examples that follow.
  • the present invention further provides a method of immunizing an avian comprising administering to the avian a transgenic plant containing an effective amount of a vaccine comprising an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the plant is a tobacco plant.
  • the plant is a potato plant.
  • the avian is selected from the group consisting of chicken, turkey, goose, duck, pheasant, quail, pigeon and ostrich.
  • the present invention further provides a method of immunizing an avian comprising administering to the avian bacteria containing an effective amount of a vaccine containing an effective immunizing amount of empty particles of IBDV.
  • the empty particles of IBDV comprise virion protein 2 (VP2), virion protein 3 (VP3), virion protein 4 (VP4).
  • the bacteria is E. Coli.
  • the avian is selected from the group consisting of chicken, turkey, goose, duck, pheasant, quail, pigeon and ostrich.
  • Immunoassays were the preferred immunoassays to assess specimens. ELISA assays are well known to those skilled in the art. Both polyclonal and monoclonal antibodies can be used in the assays. Where appropriate, other immunoassays, such as radio-immunoassays (RIA) can be used as are known to those skilled in the art. Available immunoassays are extensively described in the patent and scientific literature.
  • RIA radio-immunoassays
  • Antibodies may be monoclonal, polyclonal or recombinant. Conveniently, the antibodies may be prepared against the immunogen or portion thereof, for example a synthetic peptide based on the sequence, or may be prepared recombinantly by cloning techniques, or the
  • Immunogens can be used to produce antibodies by standard
  • Antibody fragments may also be prepared from the antibodies and include Fab,
  • polyclonal antibodies For producing polyclonal antibodies in a host, such as a rabbit or goat,
  • the host is immunized with the immunogen or immunogen fragment, generally with an adjuvant and, if necessary, coupled to a carrier.
  • the immunogen are collected from the sera. Further, the polyclonal antibody
  • the sera can be absorbed against related immunogens so that no cross-reactive antibodies remain in the sera, rendering it monospecific.
  • the technique involves hyperimmunization of an appropriate donor, generally a mouse, with the
  • splenic antibody producing cells These cells are fused to a cell having immortality, such as a myeloma cell, to provide a fused cell hybrid that has immortality and secretes the required antibody.
  • a cell having immortality such as a myeloma cell
  • the cells are then cultured in bulk and the monoclonal antibodies harvested from the culture media for use.
  • RNAs from antibody producing B-lymphocytes of animals, or hybridoma are reverse-transcribed to obtain complimentary DNAs (cDNAs).
  • Antibody cDNA which can be full or partial length, is amplified and cloned into a phage of a plasmid.
  • the cDNA can be a partial length of heavy and light chain cDNA, separated or connected by a linker.
  • the antibody or antibody fragment is expressed using a suitable expression system to obtain recombinant antibody.
  • Antibody cDNA can also be obtained by screening pertinent expression libraries.
  • the antibody can be bound to a solid support substrate, conjugated with a detectable moiety, or be both bound and conjugated as is well known in the art.
  • a solid support substrate conjugated with a detectable moiety
  • the binding of antibodies to a solid support substrate is also well known in the art.
  • Harlow and Lane Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Publications, New York), 1988, and Borrebaeck, Antibody Engineering - A Practical Guide, (W.H.
  • the detectable moieties contemplated with the present invention can include, but are not limited to, fluorescent, metallic, enzymatic and radioactive markers such as biotin, gold, ferritin, alkaline phosphatase, -galactosidase, peroxidase, urease, fluorescein, rhodamine, tritium, 14 C and 125 l.
  • nucleic acid is replaceable by any other nucleic acid encoding an IBDV polypeptide or any other nucleic acid encoding other disease related viral proteins and still fall within the scope of the present invention.
  • EXAMPLE 1 Cloning and Expression of INFECTIOUS BURSAL DISEASE VIRUS (IBDV) fragment A in E. Coli To be able to express the structural proteins in a way that they will be assembled in a recombinant virion, the entire coding sequence of fragment A was cloned into pET E. Coli expression vector.
  • IBDV INFECTIOUS BURSAL DISEASE VIRUS
  • Primer IBDV #876 from position 15 to position 39 carries a Not I site at the 5' terminus and Nde I site (CATATG) with the first viral ATG.
  • the reverse primer in this pair was IBDV #12 from position 1806 to 1830.
  • the primer carries the unique Bam HI site of fragment A.
  • the other pair is primer IBDV #18 starting from 1807 to 1831 carrying the same (fragment A) unique Bam HI site and the reverse primer IBDV# 3068 from position 3044 to 3068 containing a Not I site at the 5' prime end.
  • Figure 2A shows the amplification and cloning of the IBDV A genome.
  • the amplification of IBDV genome is shown as follows: Lane 1 , the 1.8 kbp of IBDV PCR product; Lane 2, the 1.2 kbp of IBDV PCR product, Lane M. 1 kb ladder.
  • Figure 2B are shown the clones of the IBDV fragments after digestion by Not l-Bam HI as follows: Lane 1 , plBDV1.2 containing 1.2 kbp fragment; Lanes 2-4, Clones plBDV1.8 carrying the 1.8 kbp fragment.
  • FIG. 2C are depicted the clones of pKVI201 203 and 204 bearing the 3.1 kbp IBDV fragment after Not l-Bam HI digestion. More specifically, in Figure 2C Lanes 1-3 have arrows at the left side of each of the figures indicating IBDV cDNA fragments.
  • Figure 3 depicts the cloning of the IBDV A genome into pET21 a vector.
  • Figure 3A shows a schematic representation of pET21a.
  • Figure 3B is a photograph of a gel wherein Lanes 1 , 2 are the vectors pKVI 206, 207 after Xba l-Not I digestion.
  • Figure 3C is a schematic representation of pKVI206 vector.
  • BL21 cells carrying the pKBVI206 plasmids were treated with 1mM IPTG for 14 hours at room temperature and the cell extracts were subjected to SDS polyacrylamide gel electrophoresis. From the coomassie blue staining one could detect a bend of 32 kDa similar in size to the mature IBDV VP3 ( Figure 5A, lane 2). This band does not appear in the control BL21 cells carrying pET21a and in uninduced BL21-pKVI206 ( Figure 5A, Lanes 1 and 3 respectively).
  • the presence of the mature viral proteins in the induced BL21-pKVI206 cells is an indication that the large IBDV polyprotein was processed into mature proteins as was expected.
  • Immuno-electron-microscopy analysis revealed virion-like structures in the induced cells following expression. Electron microscopy grids covered with anti-IBDV serum were used to capture viral proteins and the same serum was used to decorate the captured virions. In extracts taken from induced BL21 pKVI206, virion structures were present which appeared to be similar to those virion structures found in IBDV infected bursal cells ( Figure 6).
  • a vaccine comprising purified viral particles oil adjuvant was used to vaccinate young chicks.
  • Groups of 10-12 chickens were injected with viral empty particles purified from BL21-pKVI206 cells, viral particles purified from infected bursa, New Gamburite (Shafit's commercial vaccine), and column purified extract from BL21-pET21a cells.
  • the chickens were vaccinated again three weeks later as a booster and three weeks after that the chickens were challenged with a virulent IBDV virus isolated from the bursa of young infected chickens. Before-challenge samples were analyzed by monitoring the induction of anti-IBDV antibodies.
  • Testing included a Western blot analysis of anti-IBDV antibodies in the serum of vaccinated chicken with purified recombinant empty IBDV particles.
  • the proteins from the pKVI206-BL21 cells were electrophoresed on SDS-PAGE and subsequently blotted onto a nitrocellulose sheet. The lanes on the blot were separated, and each was reacted with the serum of a different chicken as the source of primary antibodies (Lanes 1-4).
  • the plasmid pBIN m-gfp5-ER, carrying a modified GFP gene was obtained from Dr Jim Haseloff, [Haseloff et al., "Removal of a cryptic intron and subcellular localization of green fluorescent protein are required to mark transgenic Arabidopsis plants brightly", Proc. Nat'l. Acad. Sci. USA 94, 1997, pp. 2122-2127].
  • the polylinker of pBluescipt KS and the GUS gene were introduced in place of GFP, and the plasmid was named p103.
  • the GUS gene was pulled out of p103 by digesting with Xbal and Sad.
  • This plasmid was named p203.
  • An EcoRI fragment (IBDV genes VP2, VP3 3.2 Kb) was cloned from the bursa of infected chickens by RT- PCR . The gene was inserted into the binary vector p203 at the EcoRI site, downstream from the 35S constitutive (CaMV ) promoter ( Figure 8).
  • the engineered binary plasmid was named pBi203-IBDV.
  • the orientation of the IBDV genes in the engineered binary plasmid was examined by PCR, colony hybridization and sequencing.
  • the plasmid pBi203-IBDV was introduced into the Agrobacterium tumefaciens strain LBA4404 by electroporation (Bio-Rad Gene Pulser II apparatus, cuvette gap 0.2 cm, voltage 2.5kV Capacitor 25 F. Resistor 200 Time Constant 4-5 msec).
  • the electroporated bacteria were subsequently selected by PCR and by selection with the antibiotic rifampicin.
  • Leaf disks of tobacco plants (Nicotiana tabacum cv. SR1 or NN) or mini tuber disks from potatoes (Solanum tuberosum cv. Desiree) were transformed according to the technique detailed in Horsch et al. ["RT: A simple and general method for transferring genes into plants", Science 227 ' , 1985, pp. 1229-1231] for tobacco plants and as described by Snyder and Belknap, [”A modified method for routine Agrobacterium mediated transformatino of in vitro grown potato microtubers", Plant Cell Reports 12, 1993, pp. 324-327] with the transfected A. tumefaciens harboring p203Bi-IBDV and incubated on a regeneration medium composed of MS salt and vitamin mixture (M0222
  • Transgenic rooted plantlets were transferred to soil and grown in a greenhouse at 25°C under a 16-hours light / 8-hours dark daily cycle. These plants were also self-pollinated, and their seeds were collected and germinated on Km-containing MS medium to have R1 generation.
  • PCR reaction mixture (25 ⁇ l) consisted of 25 mM Tris HCl, pH 9.3, 50 mM KCI, 2
  • each primer primers for VP2: sense #93, and antisense # 92 (Stram et al., "Applications of the polymerase chain reaction to detect infection Bursal Disease Virus in natuarlly infected chickens", Avian Diseases 38, 1994, pp. 879-884), DNA template 150-300 ng, 2.5 units of Taq DNA polymerase (Advanced Biotechnology).
  • the reaction mixture was subjected to initial denaturation of the genomic DNA at 94° C for 10 minutes, followed by 1 minute at 56° C.
  • reaction mixture was then incubated for 2 minutes at 72° C and further subjected to 40 PCR cycles (each consisting of 30 seconds at 92° C, 30 seconds at 55° C, and 30 seconds at 72°C), concluding with a 7 minutes incubation at 72°C.
  • 40 PCR cycles each consisting of 30 seconds at 92° C, 30 seconds at 55° C, and 30 seconds at 72°C
  • RT transcription
  • transcriptase Promega
  • the reaction was carried out at 42°C for 1 hour. All the RT reaction mixture served as a template for a PCR, carried out at 94°C for 10 minutes followed by 30 cycles of 94°C (30 seconds); 58°C (30 seconds); 72°C (30 seconds).
  • the sequences of the IBDV PCR primers are as described by Stram et al. (1994), or of a NOS terminator (this primer is located on the part of Nos- terminator beyond the poly A site. Therefore it will be found on the DNA but not on the transcribed RNA).
  • the reaction products were separated on a 1.5% agarose gel.
  • Figure 9A depicts in Lane 1 the positive control which is the PCR using the binary plasmids pBi203 as a template.
  • Lanes 2-6 and 14-15 show the PCR results using transgenic potato tuber DNA from the respective lines as a template.
  • Lane NN the negative control, depicts the PCR product using non-transgenic potato tuber DNA as a template.
  • Lane PBR Alu shows the DNA of molecular size markers.
  • Lane 9B Lane 1 is the negative control which shows the PCR product using the binary plasmids pBi203 as a template.
  • Lanes 2-6 and 14-15 show the RT-PCR results using transgenic potato tuber RNA from the respective lines as a template.
  • Lane NN the negative control, depicts the RT-PCR product using non-transgenic potato tuber RNA from lane 3 as a template, however the RT enzyme was omitted from the reaction mixture.
  • Protein was extracted from transgenic plants (tobacco or potato) in the following extraction buffer (2 ml/gr fresh tissue) [Edelbaum et al, "Two antiviral proteins from tobacco: Purification and characterization by monoclonal antibodies to human SYMBOL 98 ⁇ f "Symbols 12 - interferon", Proc. National Academy Sci. USA 87, 1990, pp. 588-592]. 20 mM Tris-HCI, pH 7.5, 150 mM KCI, 7 mM Mg acetate, 150 mM glucose, 30 mM 2-mercaptoethanol, 1 mM
  • EDTA 1 M benzamidine, 100 ⁇ M phenylmethylsulfonyl fluoride, 10% (v/v) glycerol and 0.5%(v/v) NP-40.
  • the homogenate was centrifuged at 15,000 g, 4° C for 15 minutes and the supernatant fluid was aliquoted and kept at -80° C. Protein content was determined according to Bradford ["A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of dye binding", Anal. Biochem. 72, 1976, pp. 248-254].
  • Proteins were electrophoresed in 12.5% SDS-polyacrylamide gels according to Laemmli ["Cleavage of structural proteins during the assembly of the head of bacteriophage T4", Nature 227, 1970, pp. 680-685] and electroblotted onto nitrocellulose membranes according to Towbin et al. ["Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications:", Proc. Nat'l. Acad. Sci. USA, 76, 1979, pp.4350-4354]. The membrane was incubated with Rabbit anti IBDV antiserum at a 1 :100 or 1 :500 dilution for 16 hours at 4° C.
  • Leaf or tuber tissue (3-8 g) were ground in by mortar and pestle in liquid N2.
  • FIG. 11 shows the scanning electron microscope (SEM) microscopy of IBDV particles in transgenic potato and tobacco plants.
  • transgenic tobacco and potato plants are of Ro generation. They all have flowered and set seeds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un vaccin stable protégeant contre une maladie, qui contient des protéines virales exprimées de manière transgénique dans des cellules végétales. L'invention concerne aussi un vaccin stable protégeant contre une maladie, qui contient une protéine virale et des séquences codantes clonées dans un système d'expression d'E. Coli ; un procédé de vaccination qui comporte les étapes consistant à exprimer de manière transgénique, dans des cellules végétales, des protéines virales capables de protéger contre une maladie et à administrer les cellules végétales à un animal nécessitant une telle vaccination. L'invention concerne de plus un procédé de vaccination qui comporte les étapes consistant à cloner, dans un système d'expression d'E. Coli, une protéine virale et des séquences codantes capables de protéger contre une maladie et à administrer les bactéries d'E. Coli à un animal nécessitant une telle vaccination.
PCT/IL2000/000360 2000-06-19 2000-06-19 Vaccins recombines contre le virus de la bursite infectieuse WO2001097839A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2000252449A AU2000252449A1 (en) 2000-06-19 2000-06-19 Recombinant vaccines against infectious bursal disease virus
EP00937165A EP1296710A4 (fr) 2000-06-19 2000-06-19 Vaccins recombines contre le virus de la bursite infectieuse
PCT/IL2000/000360 WO2001097839A1 (fr) 2000-06-19 2000-06-19 Vaccins recombines contre le virus de la bursite infectieuse

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IL2000/000360 WO2001097839A1 (fr) 2000-06-19 2000-06-19 Vaccins recombines contre le virus de la bursite infectieuse

Publications (1)

Publication Number Publication Date
WO2001097839A1 true WO2001097839A1 (fr) 2001-12-27

Family

ID=11042982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000360 WO2001097839A1 (fr) 2000-06-19 2000-06-19 Vaccins recombines contre le virus de la bursite infectieuse

Country Status (3)

Country Link
EP (1) EP1296710A4 (fr)
AU (1) AU2000252449A1 (fr)
WO (1) WO2001097839A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005071068A1 (fr) * 2004-01-21 2005-08-04 Consejo Superior De Investigaciones Científicas Capsides vides (vlps(-vp4) du virus de la bursite infectieuse(ibdv), son procede d'obtention et ses applications
EP1974744A1 (fr) * 2000-06-16 2008-10-01 Hadasit Medical Research Services And Development Ltd. Immunisation par administration orale d'un vaccin avec un produit comestible
US7476387B2 (en) 2005-07-15 2009-01-13 Chimera Pharma S.L.U. Chimeric empty viral-like particles derived from the infectious bursal disease virus (IBDV), process for their production and applications
CN112442131A (zh) * 2019-08-28 2021-03-05 中国农业科学院生物技术研究所 基于自组装铁蛋白纳米抗原颗粒及由其制备的传染性法氏囊病疫苗和应用
WO2023227599A1 (fr) 2022-05-23 2023-11-30 Atlantic Technological University Composition de revêtement antimicrobienne

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5605827A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus
US5641490A (en) * 1991-03-07 1997-06-24 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222842B1 (fr) * 1985-05-30 1995-05-10 Commonwealth Scientific And Industrial Research Organisation Clonage et expression des immunogenes protecteurs d'hote du virus de la bursite infectieuse (ibdv)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956282A (en) * 1985-07-29 1990-09-11 Calgene, Inc. Mammalian peptide expression in plant cells
US5641490A (en) * 1991-03-07 1997-06-24 Virogenetics Corporation Infectious bursal disease virus recombinant poxvirus vaccine
US5605827A (en) * 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus
US5788970A (en) * 1994-03-29 1998-08-04 The University Of Maryland College Park Chimeric infectious bursal disease virus CDNA clones, expression products and vaccines based thereon

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1296710A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974744A1 (fr) * 2000-06-16 2008-10-01 Hadasit Medical Research Services And Development Ltd. Immunisation par administration orale d'un vaccin avec un produit comestible
WO2005071068A1 (fr) * 2004-01-21 2005-08-04 Consejo Superior De Investigaciones Científicas Capsides vides (vlps(-vp4) du virus de la bursite infectieuse(ibdv), son procede d'obtention et ses applications
US7476387B2 (en) 2005-07-15 2009-01-13 Chimera Pharma S.L.U. Chimeric empty viral-like particles derived from the infectious bursal disease virus (IBDV), process for their production and applications
CN112442131A (zh) * 2019-08-28 2021-03-05 中国农业科学院生物技术研究所 基于自组装铁蛋白纳米抗原颗粒及由其制备的传染性法氏囊病疫苗和应用
CN112442131B (zh) * 2019-08-28 2022-08-12 中国农业科学院生物技术研究所 基于自组装铁蛋白纳米抗原颗粒及由其制备的传染性法氏囊病疫苗和应用
WO2023227599A1 (fr) 2022-05-23 2023-11-30 Atlantic Technological University Composition de revêtement antimicrobienne

Also Published As

Publication number Publication date
AU2000252449A1 (en) 2002-01-02
EP1296710A1 (fr) 2003-04-02
EP1296710A4 (fr) 2004-05-12

Similar Documents

Publication Publication Date Title
US6528063B2 (en) Recombinant vaccines against IBDV
US6194560B1 (en) Oral immunization with transgenic plants
CN100393870C (zh) 用于制备免疫保护性组合物的载体和来源于转基因植物的细胞
Warzecha et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato
Shchelkunov et al. Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses
US20050232949A1 (en) Vaccines expressed in plants
US6395964B1 (en) Oral immunization with transgenic plants
WO1990002484A1 (fr) Immunisation par voie orale a l'aide de plantes transgeniques
Kumar et al. Production of hepatitis B surface antigen in recombinant plant systems: an update
CN101166827A (zh) 在植物中表达蛋白质
US7964403B2 (en) Preparation of vaccine master cell lines using recombinant plant suspension cultures
Rosales-Mendoza et al. Transgenic carrot tap roots expressing an immunogenic F1–V fusion protein from Yersinia pestis are immunogenic in mice
CN105755015B (zh) 表达鸡传染性法氏囊病毒病毒样颗粒的重组酵母菌株及其所表达的蛋白和用途
US20120171230A1 (en) Oral vaccines produced and administered using edible micro-organism
US20050166290A1 (en) Expression cassettes and methods for delivery of animal vaccines
Kehm et al. Expression of immunogenic Puumala virus nucleocapsid protein in transgenic tobacco and potato plants
EP1296710A1 (fr) Vaccins recombines contre le virus de la bursite infectieuse
EP1573014A2 (fr) Immunisation de poissons a l'aide de proteines recombinantes exprimees dans des plantes
US6867353B2 (en) Production method of recombinant rotavirus structural proteins and vaccine composition
CN101591647A (zh) 含有外源性内表位的病毒颗粒
CN102676546B (zh) Pgene基因以及在番茄系统中表达pgene功能蛋白的方法
US20040166121A1 (en) Vaccines expressed in plants
CN116656630B (zh) 重组鸭瘟病毒疫苗及其构建方法和应用
JP2003116385A (ja) 日本脳炎ワクチンをコードする遺伝子を含むトランスジェニック植物
CA2221843A1 (fr) Production, dans des plantes, de vaccins oraux contre le syndrome dysgenesique et respiratoire du porc

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2000937165

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937165

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000937165

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载